Epigenetic Analysis of IGF2 in Serous Epithelial Ovarian Tumors
| Characteristic | n | Age (Avg) | CTCF-1* | CTCF-6*,† | IGF2 DMR‡ | LOI§ | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Borderline | 5 | 41.4 | 2/2 | 0/5 | 2/3 | 0/2 | ||||||
| Early stage (I/II) | 9 | 55.2 | 6/2 | 1/8 | 4/5 | 0/2 | ||||||
| Advanced stage (III/IV) | 64 | 60.9 | 37/16 | 28/29 | 14/44 | 5/16 | ||||||
| Normal lymphocytes∥ | 43 | N/A | 3/30 | 2/37 | 2/41 | N/A | ||||||
| Age at diagnosis (y) | ||||||||||||
| ≤50 | 17 | 44.9 | 10/5 | 5/11 | 7/10 | 1/3 | ||||||
| >50 | 56 | 64.8 | 33/13 | 24/25 | 11/39 | 4/15 | ||||||
| Fisher's exact P | 1.00 | 0.27 | 0.21 | 1.00 | ||||||||
| Survival (advanced stage) | ||||||||||||
| ≤3 y postdiagnosis | 30 | 59.7 | 16/6 | 12/13 | 7/20 | 3/7 | ||||||
| ≥7 y postdiagnosis | 24 | 60.1 | 15/6 | 11/11 | 6/15 | 2/7 | ||||||
| Fisher's exact P | 1.00 | 1.00 | 1.00 | 1.00 | ||||||||
| IGF2 expression | ||||||||||||
| Microarray ≤90 | 26 | 57.6 | 11/9 | 5/17 | 10/14 | 4/3 | ||||||
| Microarray >90 | 35 | 60.7 | 25/5 | 18/14 | 7/24 | 1/12 | ||||||
| Fisher's exact P | 0.05 | 0.02 | 0.15 | 0.03 | ||||||||
| Epigenetic features | ||||||||||||
| Borderline vs malignant | 0.58¶ | 0.07¶ | 0.61¶ | 1.00¶ | ||||||||
| Stage I/II vs III/IV | 1.00¶ | 0.07¶ | 0.24¶ | 1.00¶ | ||||||||
| Malignant vs lymphocytes | <0.0001¶ | <0.0001¶ | 0.004¶ | N/A | ||||||||
Abbreviation: N/A, not applicable.
↵* Number exhibiting hypermethylation/number exhibiting differential methylation.
↵† One sample was not tabulated here because it was hypermethylated at CTCF-6.
↵‡ Number exhibiting hypomethylation/number exhibiting differential methylation.
↵§ Number with loss of IGF2 imprinting/number with maintenance of imprinting.
↵∥ Normal lymphocytes were from individuals without evident malignancy.
↵¶ Fisher's exact P.